Besides, Tavan et al. reported that UPF3B was up-regulated in serum samples of cholangiocarcinoma patients compared to benign biliary tract diseases, hence can be regarded as a biomarker for differentiating cholangiocarcinoma from benign biliary tract diseases (36). This evidence concerns the gene UPF3B and cholangiocarcinoma.